Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $1,000,020.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 14,286 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $70.00, for a total value of $1,000,020.00. Following the completion of the transaction, the chief executive officer directly owned 47,420 shares of the company’s stock, valued at approximately $3,319,400. The trade was a 23.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, August 18th, Ryan Fukushima sold 41,095 shares of Tempus AI stock. The shares were sold at an average price of $49.61, for a total transaction of $2,038,722.95.
• On Friday, August 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $50.04, for a total transaction of $1,000,800.00.
• On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The shares were sold at an average price of $46.19, for a total transaction of $1,100,153.42.
• On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The shares were sold at an average price of $57.39, for a total transaction of $1,910,168.76.
• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00.

Tempus AI Trading Up 3.2%

Shares of NASDAQ:TEM opened at $70.69 on Friday. The company has a 50 day moving average of $54.37 and a 200-day moving average of $51.71. The firm has a market cap of $12.75 billion, a P/E ratio of -49.09 and a beta of 3.58. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $104.32. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same period last year, the firm posted ($0.22) earnings per share. The business’s revenue was up 21.6% on a year-over-year basis. As a group, analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently modified their holdings of the stock. Pictet Asset Management Holding SA boosted its position in shares of Tempus AI by 291.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after purchasing an additional 36,096 shares during the period. Bogart Wealth LLC raised its holdings in Tempus AI by 365,087.5% during the 4th quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock worth $3,450,000 after buying an additional 58,414 shares during the period. Eagle Health Investments LP acquired a new stake in Tempus AI during the 1st quarter worth about $11,588,000. Alethea Capital Management LLC purchased a new stake in Tempus AI during the fourth quarter valued at about $1,863,000. Finally, Hussman Strategic Advisors Inc. lifted its stake in Tempus AI by 100.0% during the fourth quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the company’s stock valued at $2,480,000 after buying an additional 21,000 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TEM has been the subject of several research analyst reports. Weiss Ratings upgraded Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a research report on Friday, July 31st. Piper Sandler cut their price target on shares of Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a report on Tuesday, August 4th. TD Cowen restated a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Finally, HC Wainwright lowered their price objective on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $65.69.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: The company received FDA clearance for an ECG-based tool designed to flag pulmonary hypertension. The clearance expands Tempus AI’s clinical technology offerings and supports its strategy of applying artificial intelligence to healthcare diagnostics. Tempus AI Wins FDA Clearance for ECG Tool
• Positive Sentiment: Tempus AI also benefited from a read-through from Moderna and Merck’s positive Phase 3 melanoma results for personalized cancer therapy V940 combined with Keytruda. Personalis, which Tempus acquired for approximately $1.5 billion, supported the trial, potentially validating the strategic value of that acquisition and its role in precision oncology. Detailed trial data are still pending. Tempus AI and Moderna’s Melanoma Results
• Neutral Sentiment: Tempus AI’s latest reported quarter showed revenue growth of 21.6% year over year to $382.5 million and a smaller-than-expected loss, providing fundamental support for the recent rebound. However, the company remains unprofitable, and analysts’ average rating is “Hold” with a consensus price target of $65.69.
• Negative Sentiment: CEO Eric Lefkofsky sold 250,000 shares for roughly $17.1 million in two transactions, reducing his direct ownership by about two-thirds. CEO Ryan Fukushima also sold 14,286 shares worth approximately $1 million. The transactions were made under pre-arranged Rule 10b5-1 plans, which reduces their value as a signal of management’s current outlook but nevertheless adds selling pressure. SEC Insider Sale Filing
• Negative Sentiment: Cathie Wood’s investment firm reportedly sold approximately $4 million of Tempus AI shares, adding to concerns about profit-taking after the stock’s sharp recovery.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.